TAGRISSO 40MG

Tagrisso 40mg defines

A Tagrisso 40mg tablet is enclosing a functioning substance known as Osimeritinib, which is in the past known as Mereletinib.

Osimeritinib is an inescapable, specifically veered off epidermal development factor receptor prohibitor, containing hostile to malignancy movement.

The pharmacological class of Tagrisso 40mg is tyrosine kinase prohibitor. Osimeritinib is expressed as third generation medicine, which is accessible in tablet shape.

Tagrisso 40mg indication

A Tagrisso 40mg tablet is widely used as first line treatment for advanced non-small cell lung cancer with EGFR mutation positive patients.

Tagrisso 40mg is also indicated for the treatment of patients affected with advanced EGFR T792M mutation positive NSCLC, disease has advanced on or after the tyrosine kinase inhibitor treatment

Tagrisso 40mgPharmacological action

Osimeritinib is comparative in real life when contrasted with other tyrosine kinase inhibitor drugs.

Osimeritinib is named tyrosine kinase inhibitor of epidermal improvement factor receptor which is accessible on the surface of tumor cells

Osimeritinib is non-reversibly merge with mutant kind of EGFR at 9 folds than wild sort

Precludes EGFR honing changes exon 19 Del and L858R

Prompts denies changed EGFR with T790M restriction change

Finally, cut down activity against wild kind EGFR

Tagrisso 40mg undergoes ADME

After oral administration of Tagrisso 40mg tablets, the maximum plasma concentration time reaches within 6 hours.

The volume of distribution of Osimeritinib 918L

Osimeritinib is highly bound to human plasma protein at 95%.

Metabolism of Osimeritinib occurs via oxidation, there are two major metabolites of Osimeritinib are AZ7550 & AZ5104.

The terminal half-life period of Osimeritinib 48 hours

The clearance value of Osimeritinib is 14.3L/hr.

Nearly 68% of metabolites are eliminated through feces; 14% via urine.

Tagrisso 40mg dosage management

The prescribed dose of Tagrisso tablet is, 80mg should be administered orally as once daily.

Avoid concomitant with strong CYP3A4 inducers

In case of co administration, increase the dose of Tagrisso as 160mg. it should be taken as a single dose

Then decreased the dose of Tagrisso to 80mg 3 weeks after discontinuation of CYP3A4 inducers

Tagrisso tablet should be taken with or without food

Patient are not able to take orally, tablets must be dissolved in water and drink it immediately.

Do not break, chew or crush the Tagrisso tablets.

Stop the therapy during the conditions like

QT prolongation

Symptomatic congestive heart failure

Interstitial lung disease

In pain management

Category III or severe: Restrained the Tagrisso 40mg tablet for 3 weeks

Category 0 to II: follow at 80mg or 40mg as a single dose

If no development in 3 weeks: Break off the therapy.

Concurrent use of Tagrisso with CYP3A4 inducers, the dosage of Tagrisso should be elevates to 160mg as a single dose and ensuing by 80mg for 3 weeks after discontinuation of strong CYP3A4 inducers.

Tagrisso 40mg side effects

The most common adverse effects occurred during the therapy

Cardiomyopathy

QT prolongation

Interstitial lung disease

Keratitis

Other common side effects

Diarrhea or constipation

Hyperglycemia

Hypomagnesemia

Hyponatremia

Elevation of AST & ALT

Stomatitis

Nausea

Vomiting

Rash

Nail toxicity

Pruritus

Dry skin

Headache

Cough

Dyspnea

Fatigue

Pyrexia

Loss of appetite

Respiratory tract infection

Lymphopenia

Thrombocytopenia

Anemia

Neutropenia

Tagrisso 40mg drugs Interaction

Tagrisso 40mg tablets concomitant with strong CYP3A4 inducers, leads to reducing the exposure of Osimeritinib, this may causes reducing the effect of Tagrisso 40mg.

Avoid the concurrent use of strong CYP3A4 inducers with Tagrisso 40mg tablets.

Tagrisso 40mg tablet concomitant with BCRP substrates may causes elevating the exposure of BCRP substrates. Thus, results as raising the adverse effects related to BCRP substrates

Avoid concurrent use of Tagrisso 40mg tablets with drug which activate the QT prolongation. In this case patients should be experienced with periodic ECG monitoring.

Tagrisso 40mg usage in

Pregnancy

Pregnancy category of Osimeritinib is not designate

While using Tagrisso 40mg tablet causes embryo fetal harm

Lactation

Milk feeding should not be recommended during lactation period.

Pediatric

The efficacy of Osimeritinib in pediatric patients has not been assessed.

Tagrisso 40mg warning

Some of the adverse effects occur during the therapy

Interstitial lung disease: To avoid this problem, withheld or discontinue the Tagrisso 40mg tablets.

Keratitis: Monitor the manifestation of keratitis frequently and provide supportive measures

Embryo fetal toxicity:Tagrisso 40mg tablet used in pregnancy period causes fetal damage.

QTc extension: Avoid concurrent use of Tagrisso 40mg with drug prolong the QTc

Cardiomyopathy: Periodic cardiac monitoring is assessed; in this condition discontinue the therapy.

Tagrisso 40mg missed dose

In case of missed dose, do not take the missed dose and follow the regular dosing schedule.

Tagrisso 40mg contraindication

Contraindication is not occurred during the treatment.

In some patients, anaphylactic reactions may occur due to patients may contraindicated to the component of Tagrisso 40mg tablet.

Tagrisso 40mg storage

The storage condition of Tagrisso 40mg tablet is, stored at 25^oC.

Protect the tablet carton from moisture, heat and light.